University of Bordeaux, National Institute for Health and Medical Research (Inserm), Research Institute for Sustainable Development (IRD), Bordeaux Population Health Center, UMR 1219, Bordeaux, France; The Alliance for International Medical Action, Dakar, Senegal.
The Alliance for International Medical Action, Dakar, Senegal.
Int J Infect Dis. 2021 Dec;113:166-167. doi: 10.1016/j.ijid.2021.09.053. Epub 2021 Sep 26.
With the development of therapeutics and vaccine against Ebola virus disease (EVD), the question of post-exposure prophylaxis for high-risk contact has emerged. Immunotherapies (monoclonal antibodies [mAbs]) recently validated for treating infected patients appear to be a good candidate for protecting contacts.
During the tenth EVD outbreak in the Democratic Republic of the Congo, we have administrated mAbs (Mab114 or REGN-EB3) to high and intermediate-risk contacts of EVD patients.
Overall, 23 non-vaccinated contacts received mAbs after a median delay between contact and post-exposure prophylaxis of 1 day (interquartile range 1-2). All contacts were free of symptoms, and all had negative reverse transcriptase-polymerase chain reaction 14 days after the contact.
Immunotherapies appear to be promising candidates to protect EVD contacts. Interaction with vaccine needs to be analyzed and a larger study on efficacy conducted.
随着埃博拉病毒病（EVD）治疗方法和疫苗的发展，高风险接触者的暴露后预防问题已经出现。最近被验证可用于治疗感染患者的免疫疗法（单克隆抗体[mAbs]）似乎是保护接触者的一个很好的候选药物。
在刚果民主共和国的第十次埃博拉病毒病暴发期间，我们给 EVD 患者的高风险和中风险接触者使用了 mAbs（Mab114 或 REGN-EB3）。
总体而言，23 名未接种疫苗的接触者在接触后接受了 mAbs 治疗，暴露后预防的中位数时间为 1 天（四分位距 1-2）。所有接触者均无症状，所有接触者在接触后 14 天内逆转录酶-聚合酶链反应均为阴性。
免疫疗法似乎是保护 EVD 接触者的有前途的候选药物。需要分析其与疫苗的相互作用，并开展更大规模的疗效研究。
